预防性艾滋病毒疫苗研究中的伦理问题

HIV therapy Pub Date : 2009-04-30 DOI:10.2217/HIV.09.7
R. Macklin
{"title":"预防性艾滋病毒疫苗研究中的伦理问题","authors":"R. Macklin","doi":"10.2217/HIV.09.7","DOIUrl":null,"url":null,"abstract":"It is widely acknowledged that the best hope of slowing the worldwide HIV epidemic lies in the development of a safe and effective preventive method. Yet, like any other research enterprise, the quest for an HIV vaccine requires adherence to ethical standards. Debates surrounding appropriate ethical standards for preventive vaccine research include, but are not limited to, the following questions. What should be provided to participants in vaccine trials who acquire HIV infection during the trial? Once an efficacious vaccine is approved by regulatory authorities and becomes available, is it acceptable to use a placebo for the control group in future vaccine trials? As other modes of prevention are found to be effective, should a prevention package be provided to all participants in HIV vaccine trials? What obligation exists to provide successful vaccine products to the community or country when trials have successful outcomes?","PeriodicalId":88510,"journal":{"name":"HIV therapy","volume":"31 1","pages":"229-236"},"PeriodicalIF":0.0000,"publicationDate":"2009-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"8","resultStr":"{\"title\":\"Ethics in preventive HIV vaccine research\",\"authors\":\"R. Macklin\",\"doi\":\"10.2217/HIV.09.7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"It is widely acknowledged that the best hope of slowing the worldwide HIV epidemic lies in the development of a safe and effective preventive method. Yet, like any other research enterprise, the quest for an HIV vaccine requires adherence to ethical standards. Debates surrounding appropriate ethical standards for preventive vaccine research include, but are not limited to, the following questions. What should be provided to participants in vaccine trials who acquire HIV infection during the trial? Once an efficacious vaccine is approved by regulatory authorities and becomes available, is it acceptable to use a placebo for the control group in future vaccine trials? As other modes of prevention are found to be effective, should a prevention package be provided to all participants in HIV vaccine trials? What obligation exists to provide successful vaccine products to the community or country when trials have successful outcomes?\",\"PeriodicalId\":88510,\"journal\":{\"name\":\"HIV therapy\",\"volume\":\"31 1\",\"pages\":\"229-236\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2009-04-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"8\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"HIV therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/HIV.09.7\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"HIV therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/HIV.09.7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 8

摘要

人们普遍承认,减缓全世界艾滋病毒流行的最大希望在于发展一种安全有效的预防方法。然而,像任何其他研究事业一样,寻求艾滋病毒疫苗需要遵守道德标准。围绕预防性疫苗研究的适当伦理标准的辩论包括但不限于以下问题。在疫苗试验期间感染艾滋病毒的参与者应该得到什么?一旦一种有效的疫苗获得监管机构的批准并可供使用,在未来的疫苗试验中,是否可以接受对照组使用安慰剂?在发现其他预防方式有效的情况下,是否应向所有艾滋病毒疫苗试验参与者提供一揽子预防措施?当试验取得成功结果时,有什么义务向社区或国家提供成功的疫苗产品?
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Ethics in preventive HIV vaccine research
It is widely acknowledged that the best hope of slowing the worldwide HIV epidemic lies in the development of a safe and effective preventive method. Yet, like any other research enterprise, the quest for an HIV vaccine requires adherence to ethical standards. Debates surrounding appropriate ethical standards for preventive vaccine research include, but are not limited to, the following questions. What should be provided to participants in vaccine trials who acquire HIV infection during the trial? Once an efficacious vaccine is approved by regulatory authorities and becomes available, is it acceptable to use a placebo for the control group in future vaccine trials? As other modes of prevention are found to be effective, should a prevention package be provided to all participants in HIV vaccine trials? What obligation exists to provide successful vaccine products to the community or country when trials have successful outcomes?
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
HIV Therapy merges with Future Virology HIV-related lymphoma The intersection between HIV and syphilis in men who have sex with men: some fresh perspectives. Premature onset of cardiovascular disease in HIV-infected individuals: the drugs and the virus Cervical cancer prevention in HIV-infected women in resource-limited settings
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1